Potent, selective and reversible hMAO-B inhibition by benzalphthalides: Synthesis, enzymatic and cellular evaluations and virtual docking and predictive studies
Open Access
- 3 March 2024
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 146, 107255
Abstract
No abstract availableKeywords
Funding Information
- Xunta de Galicia Consellería de Cultura Educacion e Ordenación Universitaria
- European Regional Development Fund
- Ministerio de Economía y Competitividad
This publication has 38 references indexed in Scilit:
- 6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson’s disease treatmentBioorganic Chemistry, 2022
- Synthesis and in vitro study of nitro- and methoxy-2-phenylbenzofurans as human monoamine oxidase inhibitorsBioorganic Chemistry, 2021
- Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotectionJournal of Neural Transmission, 2015
- Safinamide: First Global ApprovalDrugs, 2015
- Insight into the Functional and Structural Properties of 3‐Arylcoumarin as an Interesting Scaffold in Monoamine Oxidase B InhibitionChemMedChem, 2014
- MAO Inhibitory Activity of 2‐Arylbenzofurans versus 3‐Arylcoumarins: Synthesis, in vitro Study, and Docking CalculationsChemMedChem, 2013
- 8‐Substituted 3‐Arylcoumarins as Potent and Selective MAO‐B Inhibitors: Synthesis, Pharmacological Evaluation, and Docking StudiesChemMedChem, 2012
- The 6-Hydroxydopamine model of parkinson’s diseaseNeurotoxicity Research, 2007
- Oxidative stress in Parkinson's diseaseAnnals of Neurology, 2003
- General aspects of neurodegeneration2003